水痘ワクチンの世界市場

水痘ワクチンの世界市場は2030年までに40億米ドルに達する見込み

2024年に32億米ドルと推定される水痘ワクチンの世界市場は、分析期間2024-2030年にCAGR 3.9%で成長し、2030年には40億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである一価水痘ワクチンは、CAGR 3.2%を記録し、分析期間終了時には25億米ドルに達すると予測されます。混合水痘ワクチンセグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は8億6,690万米ドルと推定、中国はCAGR 7.0％で成長すると予測

米国の水痘ワクチン市場は、2024年に8億6,690万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.0%として、2030年までに8億220万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.0%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の水痘ワクチン市場- 主要動向と促進要因のまとめ

なぜ水痘ワクチンが小児科の予防接種、公衆衛生計画、アウトブレイク予防の中心なのか？

水痘ワクチンは、特に小児における水痘・帯状疱疹ウイルス（VZV）感染の発生率減少を目的とした世界の予防接種戦略において、重要なツールとなっています。水痘は感染力が強く、感染しやすい集団に重篤な合併症を引き起こす可能性があるため、定期的な予防接種プログラムがない地域では公衆衛生上大きな負担となっています。各国政府が小児に対する普遍的なワクチン接種政策を採用するようになるにつれ、水痘ワクチンは、疾病を予防し、学校欠席を減らし、ヘルスケア資源の利用を最小限に抑える役割を果たすことから、公的・私的ヘルスケアシステムの双方で注目されるようになっています。

小児期の予防にとどまらず、免疫不全者、免疫のない成人、曝露リスクの高いヘルスケア従事者においても、ワクチン接種は不可欠です。世界の移動と都市化が加速する中、ワクチンによる免疫は、地域社会全体のアウトブレイクを予防し、施設における疾患の封じ込めを管理し、細菌性重複感染や神経学的後遺症などの水痘関連合併症による長期的なヘルスケアへの影響を軽減する上で鍵となります。

ワクチン製剤、コールドチェーンインフラストラクチャー、対象地域拡大戦略はどのように進化しているのか？

水痘ワクチン、典型的な弱毒生ウイルス製剤は、中等症から重症の疾患の予防に高い有効性を示しており、2回接種のレジメンは長期免疫を著しく増加させる。ワクチンの安定性を高め、免疫原性を改善し、特に小児や免疫不全のサブグループにおける副反応プロファイルを軽減するための研究開発が進行中です。水痘と麻疹・流行性耳下腺炎・風疹（MMRV）を含む混合ワクチンは、予防接種スケジュールを合理化し、コンプライアンスを向上させています。

コールドチェーンロジスティクス、温度安定性製剤、ワクチンバイアルモニターの進歩により、特に遠隔地や資源の乏しい地域でも、より広い範囲での接種が可能になってきています。国の予防接種プログラムでは、水痘ワクチン接種を幼児期のスケジュールに組み込む動きが加速しており、多くの場合、集団免疫目標を達成するために公的資金やドナーからの支援を受けています。就学義務化、流行対応イニシアティブ、成人のキャッチアップキャンペーンは、予防接種率と認知度をさらに高めています。

デジタルヘルスツール、予防接種追跡プラットフォーム、AIを活用した需要予測も、ワクチン提供の効率化、有害事象の監視、サプライチェーンの透明性強化に活用されています。

水痘ワクチン接種の普及を促進しているエンドユーザーと地域の保健政策は？

主な接種場所には、小児科クリニック、保健所、学校ベースの保健プログラム、旅行診療所などがあります。集団予防接種は、水痘が届出疾患に分類され、ワクチンが国の予防接種スケジュールに含まれている国で最も顕著です。高所得国の民間小児科診療所や緊急医療センターも、成人のキャッチアップ予防接種と選択的予防接種に大きく貢献しています。

北米と欧州のいくつかの地域では、小児期のワクチン接種率がほぼ普遍化し、疾病の発生率と入院率の両方が急激に低下しています。アジア太平洋地域では、日本や韓国などの国が定期的な予防接種を実施している一方で、地域ごとに段階的な予防接種プログラムを導入し、徐々に予防接種を拡大している国もあり、状況はまちまちです。ラテンアメリカと中東では、学校ベースのプログラムや世界ヘルス機関との提携を通じて、予防接種の対象を拡大しています。水痘サーベイランスがまだ限定的であるアフリカでは、都市部では予防接種の普及が進んでいるが、農村部や十分なサービスを受けていない地域ではまだ初期段階です。

水痘ワクチン市場の成長を促進する要因は何か？

水痘ワクチン市場は、早期予防接種を通じて伝染病をコントロールする公衆衛生の取り組みとともに拡大しています。世界の保健機関が疾病の根絶と長期的な負担の軽減を目標としている中、水痘ワクチン接種は、医療システム上、測定可能な利益をもたらす予防的投資と見なされるようになってきています。

主な成長要因は、小児期のワクチン接種率の増加、水痘関連合併症に対する認識の高まり、混合ワクチンの統合、予防接種インフラの拡大、国内外の保健機関による強力な政策支援などです。新たな疾病サーベイランスの枠組みやパンデミックに強い予防接種キャンペーンにより、強固でスケーラブルなワクチン供給システムの必要性がさらに高まっています。

世界の保健制度が早期予防に重点を置くようになるにつれ、水痘ワクチンは、あらゆる所得層やリスク層における普遍的な予防接種戦略の基礎となる柱となり得るだろうか。

セグメント

製品タイプ（一価水痘ワクチン、水痘混合ワクチン）、最終用途（おたふくかぜ、麻疹、風疹、水痘予防接種、帯状疱疹、予防接種、水痘予防接種）、エンドユーザー（病院、クリニック、その他エンドユーザー）

調査対象企業の例（注目の32社）

• Bavarian Nordic
• Bharat Biotech
• Bio-Med Pvt Ltd
• Curevo Vaccine
• GC Biopharma（Green Cross Holdings）
• GlaxoSmithKline plc（GSK）
• Hualan Biological Engineering Inc.
• Indian Immunologicals Ltd.
• Jiangsu Yanshen Biological Technology
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novo Medi Sciences Pvt Ltd
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Shanghai Institute of Biological Products
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Company Ltd.
• VBI Vaccines Inc.
• Zydus Cadila

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Chickenpox Vaccines Market to Reach US$4.0 Billion by 2030

The global market for Chickenpox Vaccines estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Monovalent Varicella Vaccine, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Combination Varicella Vaccine segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$866.9 Million While China is Forecast to Grow at 7.0% CAGR

The Chickenpox Vaccines market in the U.S. is estimated at US$866.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$802.2 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Chickenpox Vaccines Market - Key Trends & Drivers Summarized

Why Are Chickenpox Vaccines Central to Pediatric Immunization, Public Health Planning, and Outbreak Prevention?

Chickenpox vaccines have become a critical tool in global immunization strategies aimed at reducing the incidence of varicella-zoster virus (VZV) infections, particularly among children. Characterized by high transmissibility and the potential for severe complications in vulnerable populations, chickenpox poses a significant public health burden in regions lacking routine immunization programs. As governments increasingly adopt universal childhood vaccination policies, the chickenpox vaccine is gaining prominence in both public and private healthcare systems for its role in preventing illness, reducing school absenteeism, and minimizing healthcare resource utilization.

Beyond childhood protection, vaccination is essential in immunocompromised individuals, non-immune adults, and healthcare workers who face elevated risks of exposure. As global mobility and urbanization accelerate, vaccine-driven immunity becomes key in preventing community-wide outbreaks, managing disease containment in institutions, and lowering the long-term healthcare impact of varicella-related complications such as bacterial superinfections or neurological sequelae.

How Are Vaccine Formulations, Cold Chain Infrastructure, and Coverage Strategies Evolving to Expand Impact?

Chickenpox vaccines, typically live attenuated virus formulations, have demonstrated high efficacy in preventing moderate to severe disease, with two-dose regimens significantly increasing long-term immunity. Research and development are ongoing to enhance vaccine stability, improve immunogenicity, and reduce adverse reaction profiles, especially in pediatric and immunocompromised subgroups. Combination vaccines that include chickenpox along with measles, mumps, and rubella (MMRV) are streamlining immunization schedules and improving compliance.

Advancements in cold chain logistics, temperature-stable formulations, and vaccine vial monitors are enabling broader reach, particularly in remote and resource-limited regions. National immunization programs are increasingly integrating chickenpox vaccination into early childhood schedules, often with public funding or donor support to achieve herd immunity targets. School-entry mandates, outbreak response initiatives, and adult catch-up campaigns are further boosting coverage and awareness.

Digital health tools, immunization tracking platforms, and AI-driven demand forecasting are also being leveraged to improve vaccine delivery efficiency, monitor adverse events, and strengthen supply chain transparency.

Which End-Use Settings and Regional Health Policies Are Driving Uptake of Chickenpox Vaccination?

Primary delivery points include pediatric clinics, public health centers, school-based health programs, and travel medicine clinics. Mass vaccination is most prominent in countries where varicella is classified as a notifiable disease and where the vaccine is included in national immunization schedules. Private pediatric practices and urgent care centers in high-income countries also contribute significantly to adult catch-up and elective immunization volumes.

North America and several parts of Europe have achieved near-universal childhood vaccination coverage, resulting in sharp declines in both disease incidence and hospitalization rates. Asia-Pacific is experiencing a mixed landscape, with countries like Japan and South Korea offering routine immunization, while others are gradually scaling up access through tiered regional programs. Latin America and the Middle East are expanding coverage through school-based programs and partnerships with global health agencies. In Africa, where varicella surveillance remains limited, uptake is growing in urban areas but is still in early stages across rural and underserved communities.

What Are the Factors Driving Growth in the Chickenpox Vaccines Market?

The market for chickenpox vaccines is expanding alongside public health efforts to control communicable diseases through early immunization. As global health agencies target disease eradication and long-term burden reduction, chickenpox vaccination is increasingly viewed as a preventive investment with measurable health system benefits.

Core growth drivers include increasing childhood vaccination rates, growing awareness of varicella-related complications, integration of combination vaccines, expansion of immunization infrastructure, and strong policy support from national and international health bodies. Emerging disease surveillance frameworks and pandemic-resilient immunization campaigns are further reinforcing the need for robust, scalable vaccine delivery systems.

As global health systems strengthen their focus on early prevention, could chickenpox vaccines become a foundational pillar of universal immunization strategies across all income and risk segments?

SCOPE OF STUDY:

The report analyzes the Chickenpox Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Monovalent Varicella Vaccine, Combination Varicella Vaccine); Application (Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization, Chickenpox Vaccination); End-Use (Hospitals, Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Bavarian Nordic
• Bharat Biotech
• Bio-Med Pvt Ltd
• Curevo Vaccine
• GC Biopharma (Green Cross Holdings)
• GlaxoSmithKline plc (GSK)
• Hualan Biological Engineering Inc.
• Indian Immunologicals Ltd.
• Jiangsu Yanshen Biological Technology
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novo Medi Sciences Pvt Ltd
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Shanghai Institute of Biological Products
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Company Ltd.
• VBI Vaccines Inc.
• Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Chickenpox Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Emphasis on Pediatric Immunization Programs Throws the Spotlight on Chickenpox (Varicella) Vaccination
  • Growth in Public Health Campaigns and Expanded National Immunization Schedules Spurs Global Vaccine Uptake
  • Development of Live Attenuated and Combination MMRV Vaccines Enhances Dosing Efficiency
  • Expansion of Cold Chain and Vaccine Storage Infrastructure Supports Rural and Remote Immunization
  • Use of Two-Dose Regimens Demonstrates Improved Long-Term Immunity and Outbreak Prevention
  • Integration With School Enrollment and Travel Health Requirements Boosts Compliance Rates
  • Increased Surveillance and Outbreak Tracking Drives Demand for High-Coverage Population Immunization
  • Advancement in Vaccine Safety Profiles and Post-Market Surveillance Strengthens Public Confidence
  • Support From Global Health Organizations (e.g., WHO, GAVI) Enhances Access in Low-Income Regions
  • Rising Incidence of Adult-Onset and Breakthrough Varicella Infections Fuels Focus on Booster Strategies
  • Expansion of Combination Pediatric Vaccines Streamlines Administration and Reduces Clinic Visits
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Chickenpox Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Chickenpox Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Chickenpox Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Chickenpox Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Monovalent Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Monovalent Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Monovalent Varicella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Combination Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Combination Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Combination Varicella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Mumps by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Mumps by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Mumps by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Measles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Measles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Measles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Rubella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Varicella Immunization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Varicella Immunization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Varicella Immunization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Herpes Zoster by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Herpes Zoster by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Herpes Zoster by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Immunization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Immunization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Immunization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Chickenpox Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Chickenpox Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Chickenpox Vaccination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• JAPAN
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• CHINA
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• EUROPE
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Chickenpox Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Chickenpox Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Chickenpox Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• FRANCE
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• GERMANY
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Chickenpox Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Chickenpox Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Chickenpox Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• INDIA
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Chickenpox Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Chickenpox Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Chickenpox Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Chickenpox Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Chickenpox Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Chickenpox Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030
• AFRICA
  • Chickenpox Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Chickenpox Vaccines by Product Type - Monovalent Varicella Vaccine and Combination Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Chickenpox Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent Varicella Vaccine and Combination Varicella Vaccine for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Chickenpox Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Chickenpox Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Chickenpox Vaccines by Application - Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Chickenpox Vaccines by Application - Percentage Breakdown of Value Sales for Mumps, Measles, Rubella, Varicella Immunization, Herpes Zoster, Immunization and Chickenpox Vaccination for the Years 2015, 2025 & 2030

IV. COMPETITION